IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Heritage Financial Services LLC

Heritage Financial Services LLC reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.9% during the 3rd quarter, Holdings Channel reports. The firm owned 409 shares of the company’s stock after selling 55 shares during the quarter. Heritage Financial Services LLC’s holdings in IDEXX Laboratories were worth $207,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Legacy Capital Group California Inc. purchased a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $750,000. Values First Advisors Inc. increased its stake in shares of IDEXX Laboratories by 8.9% in the 3rd quarter. Values First Advisors Inc. now owns 2,324 shares of the company’s stock worth $1,174,000 after acquiring an additional 189 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of IDEXX Laboratories by 42.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 119,001 shares of the company’s stock worth $60,122,000 after acquiring an additional 35,750 shares during the period. IFM Investors Pty Ltd increased its position in IDEXX Laboratories by 0.3% during the third quarter. IFM Investors Pty Ltd now owns 18,947 shares of the company’s stock worth $9,572,000 after purchasing an additional 56 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after buying an additional 60 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on IDXX shares. BTIG Research initiated coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $574.13.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $452.27 on Friday. The business has a 50-day simple moving average of $486.11 and a 200-day simple moving average of $490.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a market cap of $37.35 billion, a PE ratio of 43.78, a P/E/G ratio of 4.14 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.67 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.